TrialJAMA oncology2023

Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial.

Tufia C Haddad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.